GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentation

Reuters2026/08/27 13:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

GRI Bio highlighted its idiopathic pulmonary fibrosis drug candidate GRI-0621 in a “Why Now” on-demand investor webcast.
New study results were not released; data are scheduled for presentation at the 2026 European Respiratory Society Congress on Sept. 5-9.
Management framed GRI-0621 as a once-daily oral therapy targeting inflammation, fibrosis, tissue repair to support a differentiated approach in IPF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270901PRIMZONEFULLFEED9816850) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

GRI Bio highlights IPF drug candidate GRI-0621 in “Why Now” webcast ahead of ERS 2026 data presentation

You may also like

Crypto prices